Angle completes fundraising and acquisition of Axela

The global liquid biopsy company Angle announced on Wednesday the completion of fundraising and acquisition of certain assets of Axela Inc, further to the announcement of 30 October 2017 with general admission having taken place earlier today.

Angle

9.75p

12:19 27/12/24

1.56%

0.15p

FTSE AIM All-Share

717.98

13:00 27/12/24

n/a

Support Services

10,565.93

13:00 27/12/24

0.00%

10,565.93

Axela creates tools and content to simplify multiplex biomarker detection for translational research and diagnostic testing.

While ANGLE is known for its Parsortix system, a cell separation technology, which is the subject of granted patents in Europe, the United States, Canada, India, China, Japan and Australia.

The system enables a liquid biopsy (simple blood test) to be used to provide the cells of interest with the analysis of the harvested cells hopefully opening the door to personalised cancer care, according to Angle.